Drug/Small Molecule:
nevirapine

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

Links to Unannotated Labels

These links are to labels associated with nevirapine that have not been annotated by PharmGKB.

  1. DailyMed - DrugLabel PA166105205

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2B6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2B6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2B6 *18 N/A N/A N/A
No VIP available No VIP available VA HLA-A *24:07 N/A N/A N/A
No VIP available No VIP available VA HLA-B *15:10:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *35:01:01:01 N/A N/A N/A
VIP No VIP available VA HLA-B *35:05:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *38:02:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *58:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *58:02 N/A N/A N/A
No VIP available No VIP available VA HLA-C *02:10 N/A N/A N/A
No VIP available No VIP available VA HLA-C *04:01:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-C *07:02:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-C *08:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *01:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *01:02:01 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *12:02:01 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs10276036 1000-44G>A, 167367G>A, 25213041C>T, 87180198C>T, ABCB1: IVS9 ¿44a>G
C > T
Intronic
No VIP available CA VA
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available No Clinical Annotations available VA
rs1128503 1236T>C, 167964T>C, 25043506A>G, 87550285A>G, ABCB1 1236C>T, ABCB1*8, ABCB1: c.1236T>C, ABCB1:1236C>T, ABCB1:1236T>C, Gly412=, Gly412Gly, mRNA 1654T>C, p.Gly412Gly
A > G
Not Available
Gly412Gly
No VIP available No Clinical Annotations available VA
rs1265112 1105-27A>G, 1213-27A>G, 2413852T>C, 2415135C>C, 2466369T>C, 2499948T>C, 2632765C>C, 31058019T>C, 31118019T>C, 946-27A>G
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs12721646 c.646-17C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs12721655 13778500A>G, 18079A>G, 41510282A>G, 415A>G, CYP2B6: 415A>G, K139E, Lys139Glu
A > G
Missense
Lys139Glu
No VIP available No Clinical Annotations available VA
rs12768009 168+3235G>A, 47330329G>A, 8403G>A, 8621C>T, 96525865G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs130072 1880G>A, 2039G>A, 2147G>A, 2408321C>T, 2409614C>T, 2460842C>T, 2494420C>T, 2627244C>T, 31052484C>T, 31112484C>T, Arg627Gln, Arg680Gln, Arg716Gln
C > T
Missense
Arg716Gln
No VIP available No Clinical Annotations available VA
rs1517618 7613172G>C, 882G>C, 92647645G>C, Glu294Asp
G > C
Missense
Glu294Asp
No VIP available No Clinical Annotations available VA
rs1523130 -1663T>C, 119499507T>C, 25994653T>C, 5177T>C
T > C
5' UTR
No VIP available No Clinical Annotations available VA
rs2032582 186947T>A, 186947T>G, 25193461A>C, 25193461A>T, 2677A, 2677G, 2677T, 2677T>A, 2677T>G, 3095G>T/A, 87160618A>C, 87160618A>T, 893 Ala, 893 Ser, 893 Thr, ABCB1*7, ABCB1: 2677G>T/A, ABCB1: 2677T/A>G, ABCB1: A893S, ABCB1: G2677T/A, ABCB1: c.2677G>T/A, ABCB1:2677G>A/T, ABCB1:2677G>T/A, ABCB1:A893T, Ala893Ser/Thr, MDR1, MDR1 G2677T/A, Ser893Ala, Ser893Thr, mRNA 3095G>T/A, p.Ala893Ser/Thr
A > C
A > T
Missense
Ser893Ala
Ser893Thr
No VIP available No Clinical Annotations available VA
rs2073724 2425558C>T, 2426830C>T, 2464643C>T, 2478050C>T, 2511629C>T, 2644459C>T, 31069707C>T, 31129707C>T, 722C>T, Pro241Leu
C > T
Missense
Pro241Leu
No VIP available No Clinical Annotations available VA
rs2125739 2759T>C, 2843T>C, 43352865T>C, 43412865T>C, Ile920Thr, Ile948Thr
T > C
Missense
Ile948Thr
No VIP available No Clinical Annotations available VA
rs2229107 208906T>A, 25171502A>T, 3421T>A, 87138659A>T, ABCB: S1141T, Ser1141Thr
A > T
Missense
Ser1141Thr
No VIP available No Clinical Annotations available VA
rs2233945 -558G>T, 168-57C>A, 2403206A>A, 2404499C>A, 2455729C>A, 2489306C>A, 2622083C>A, 29754C>A, 31047361C>A, 31107361C>A
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs2279343 13783481A>G, 23060A>G, 41515263A>G, 785A>G, CYP2B6*4, CYP2B6:18053A>G, CYP2B6:785A>G, CYP2B6:K262R, CYP2B6:Lys262Arg, Lys262Arg, part of CYP2B6*6
A > G
Missense
Lys262Arg
No VIP available No Clinical Annotations available VA
rs2472677 -22-7659C>T, 119518417C>T, 24087C>T, 26013563C>T, 96-7659C>T, NR1I2:63396C>T, PXR 63396C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs2562519 -43-371C>T, 40375330C>T, 89780971C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs2740574 -392G>A, 37414939C>T, 4713G>A, 5'-flanking region -392A>G, 99382096C>T, CYP3A4*1B, CYP3A4-V, CYP3A4:-392A>G
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs28371706 21916341G>A, 320C>T, 42525772G>A, 6112C>T, CYP2D6:1023 C>T, Thr107Ile
G > A
Missense
Thr107Ile
No VIP available No Clinical Annotations available VA
rs28399454 10086G>A, 1093G>A, 13619485C>T, 41351267C>T, CYP2A6:47441C>T, Val365Met
C > T
Missense
Val365Met
rs28399499 13786439T>C, 26018T>C, 41518221T>C, 983T>C, CYP2B6: 983T>C, CYP2B6:Ile328Thr, I328T, Ile328Thr, part of CYP2B6*18
T > C
Missense
Ile328Thr
No VIP available No Clinical Annotations available VA
rs3099844 2734310C>A, 2742682C>A, 2763686C>A, 2779748C>A, 2828760C>A, 2958634A>A, 31388976C>A, 31448976C>A
C > A
Not Available
No VIP available No Clinical Annotations available VA
rs3211371 13790933C>T, 1459C>T, 30512C>T, 41522715C>T, Arg487Cys, CYP2B6*5, CYP2B6*7, CYP2B6:1459C>T, CYP2B6:Arg487Cys, part of CYP2B6*1C
C > T
Missense
Arg487Cys
No VIP available No Clinical Annotations available VA
rs35979566 1172T>A, 13786816T>A, 26395T>A, 41518598T>A, Ile391Asn
T > A
Missense
Ile391Asn
No VIP available CA VA
rs3745274 13781059G>T, 20638G>T, 41512841G>T, 516G>T, CYP2B6*6, CYP2B6:516G>T, CYP2B6:Gln172His, Gln172His, Q172H
G > T
Missense
Gln172His
No VIP available No Clinical Annotations available VA
rs3842689 -205_-200delGAGAAG, -23+253_-23+258delGAGAAG, 119501400_119501405delGAGAAG, 25996546_25996551delGAGAAG, 7070_7075delGAGAAG
GAGAAG > -
5' Flanking
No VIP available No Clinical Annotations available VA
rs3892097 21915516C>T, 353-1G>A, 42524947C>T, 506-1G>A, 6937G>A, CYP2D6*4, CYP2D6:1846G>A, part of CYP2D6*4
C > T
Acceptor
No VIP available No Clinical Annotations available VA
rs58425034 13783183G>C, 22762G>C, 41514965G>C, 646-159G>C, c.646-159G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs628031 1222A>G, 160560845A>G, 64730302A>G, Met408Val
A > G
Missense
Met408Val
No VIP available No Clinical Annotations available VA
rs6545803 39356086G>T, 60534199G>T
G > T
Not Available
No VIP available No Clinical Annotations available VA
rs746647 1314-597T>C, 1473-597T>C, 1581-597T>C, 2410019A>G, 2411312G>G, 2462540A>G, 2496118A>G, 2628942G>G, 31054182A>G, 31114182A>G
A > G
Intronic
No VIP available CA VA
rs776746 12083G>A, 219-237G>A, 321-1G>A, 37303382C>T, 581-237G>A, 689-1G>A, 99270539C>T, CYP3A5*1, CYP3A5*3, CYP3A5*3C, CYP3A5:6986A>G, g.6986A>G, intron 3 splicing defect, rs776746 A>G
C > T
Acceptor
No VIP available No Clinical Annotations available VA
rs8192715
G > A
Not Available
No VIP available CA VA
rs9461684 2546933C>T, 2548992C>T, 2587161C>T, 2600285C>T, 2633936C>T, 2766684C>T, 31193444C>T, 31253444C>T
C > T
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • NEV
  • NVP
Trade Names
  • Viramune
Brand Mixture Names

PharmGKB Accession Id:
PA450616

Description

A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV infection and AIDS.

Source: Drug Bank

Indication

For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.

Source: Drug Bank

Pharmacology

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Take without regard to meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. In vivo studies in humans and in vitro studies with human liver microsomes have shown that nevirapine is extensively biotransformed via cytochrome P450 3A4 metabolism to several hydroxylated metabolites.

Source: Drug Bank

Protein Binding

60%

Source: Drug Bank

Absorption

90% (absolute bioavailability 93 +/- 9%)

Source: Drug Bank

Half-Life

45 hours

Source: Drug Bank

Toxicity

Symptoms of overdose include edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonaryinfiltrates, rash, vertigo, vomiting, and weight decrease.

Source: Drug Bank

Route of Elimination

Thus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. Only a small fraction (<5%) of the radioactivity in urine (representing <3% of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.

Source: Drug Bank

Volume of Distribution

  • 1.21 ± 0.09 L/kg

Source: Drug Bank

Chemical Properties

Chemical Formula

C15H14N4O

Source: Drug Bank

Isomeric SMILES

Cc1ccnc2c1NC(=O)c3cccnc3N2C4CC4

Source: OpenEye

Canonical SMILES

CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1

Source: Drug Bank

Average Molecular Weight

266.2979

Source: Drug Bank

Monoisotopic Molecular Weight

266.11676109

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Nevirapine Pathway, Pharmacokinetics
    Representation of candidate genes involved in biotransformation of nevirapine and its mechanism of action in an infected liver cell.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Interactions

Drug Description
nevirapine Nevirapine decreases levels/effect of atazanavir (source: Drug Bank)
nevirapine Nevirapine decreases levels/effect of atazanavir (source: Drug Bank)
nevirapine The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank)
nevirapine The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank)
nevirapine Nevirapine decreases the effect of ketoconazole (source: Drug Bank)
nevirapine Nevirapine decreases the effect of ketoconazole (source: Drug Bank)
nevirapine The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank)
nevirapine The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank)
nevirapine The antiretroviral agent decreases the effect of methadone (source: Drug Bank)
nevirapine The antiretroviral agent decreases the effect of methadone (source: Drug Bank)
nevirapine Nevirapine decreases the effect of nelfinavir (source: Drug Bank)
nevirapine Nevirapine decreases the effect of nelfinavir (source: Drug Bank)
acenocoumarol Nevirapine decreases the anticoagulant effect (source: Drug Bank)
acenocoumarol Nevirapine may decrease the anticoagulant effect of acenocoumarol. (source: Drug Bank)
anisindione Nevirapine may decrease the anticoagulant effect of anisindione. (source: Drug Bank)
atazanavir Decreases levels/effect of atazanavir (source: Drug Bank)
atazanavir Decreases levels/effect of atazanavir (source: Drug Bank)
atorvastatin The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank)
atorvastatin The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank)
dicumarol Nevirapine decreases the anticoagulant effect (source: Drug Bank)
dicumarol Nevirapine may decrease the anticoagulant effect of dicumarol. (source: Drug Bank)
ketoconazole Decreases the effect of ketoconazole (source: Drug Bank)
ketoconazole Decreases the effect of ketoconazole (source: Drug Bank)
lovastatin The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank)
lovastatin The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank)
methadone The antiretroviral agent decreases the effect of methadone (source: Drug Bank)
methadone The antiretroviral agent decreases the effect of methadone (source: Drug Bank)
nelfinavir Decreases the effect of nelfinavir (source: Drug Bank)
nelfinavir Decreases the effect of nelfinavir (source: Drug Bank)
quinupristin This combination presents an increased risk of toxicity (source: Drug Bank)
saquinavir Decreases the effect of saquinavir (source: Drug Bank)
saquinavir Decreases the effect of saquinavir (source: Drug Bank)
simvastatin The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank)
simvastatin The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank)
warfarin Nevirapine decreases the anticoagulant effect (source: Drug Bank)
warfarin Nevirapine may decrease the anticoagulant effect of warfarin by increasing metabolism of R-warfarin via CYP3A4. (source: Drug Bank)
nevirapine This combination presents an increased risk of toxicity (source: Drug Bank)
nevirapine Nevirapine may decrease the plasma concentration of Telithromycin. Consider alternate therapy. (source: Drug Bank)
nevirapine Nevirapine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided. (source: Drug Bank)
nevirapine Nevirapine, a CYP3A4 inducer, may decrease the serum concentration of Tipranavir, a CYP3A4 substrate. Monitor for changesin Tipranavir effect if Nevirapine is initiated, discontinued or dose changed. (source: Drug Bank)
nevirapine Nevirapine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. (source: Drug Bank)
nevirapine The CYP3A4 inducer, Nevirapine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nevirapine is initiated, discontinued or dose changed. (source: Drug Bank)
nevirapine The CYP3A4 inducer, Nevirapine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nevirapine is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to nevirapine: 47

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity. AIDS (London, England). 2014. Keane Niamh M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique. European journal of clinical pharmacology. 2014. Borgiani Paola, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. European journal of clinical pharmacology. 2014. Naidoo Panjasaram, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe. Current HIV research. 2013. Dhoro Milcah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients. Journal of clinical pharmacology. 2013. Coelho Antonio V C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?. Pharmacogenetics and genomics. 2013. Micheli Janine E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. European journal of clinical pharmacology. 2013. Ciccacci Cinzia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. Journal of acquired immune deficiency syndromes (1999). 2013. Phillips Elizabeth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort. PloS one. 2013. Zhu Peng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ABCC10 rs2125739 polymorphism and nevirapine-induced hepatotoxicity: lack of association in a population from Mozambique. Pharmacogenetics and genomics. 2012. Ciccacci Cinzia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. British journal of clinical pharmacology. 2012. Calcagno Andrea, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacological reviews. 2012. Michaud Veronique, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals. Therapeutic drug monitoring. 2012. Heil Sandra G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and genomics. 2012. Liptrott Neill J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics. 2012. Brown Kevin C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. Basic & clinical pharmacology & toxicology. 2011. Gozalo Claire, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spot Devices. British journal of clinical pharmacology. 2011. Calcagno A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenetics and genomics. 2011. Lehr Thorsten, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011. Chantarangsu Soranun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India. The Journal of antimicrobial chemotherapy. 2011. Swaminathan Soumya, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. The Journal of antimicrobial chemotherapy. 2011. Schipani Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Therapeutic drug monitoring. 2010. Chen Jun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert opinion on drug metabolism & toxicology. 2010. Kwara Awewura, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics. 2010. Ciccacci Cinzia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Current drug metabolism. 2009. Mo Sui-Lin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV medicine. 2009. Mahungu Tw, et al. PubMed
HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenetics and genomics. 2009. Chantarangsu Soranun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS research and therapy. 2009. Likanonsakul Sirirat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Current drug metabolism. 2008. Wang Hongbing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Diagnosis and management of HIV drug hypersensitivity. The Journal of allergy and clinical immunology. 2008. Davis Carla M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. The Journal of antimicrobial chemotherapy. 2008. Wyen Christoph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics. 2008. Gatanaga Hiroyuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. The Journal of investigative dermatology. 2008. Mockenhaupt Maja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human leukocyte antigens and drug hypersensitivity. Current opinion in allergy and clinical immunology. 2007. Chung Wen-Hung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. The Journal of pharmacology and experimental therapeutics. 2007. Faucette Stephanie R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006. Ritchie Marylyn D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006. Haas David W, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenetics and genomics. 2006. Wang Jue, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenetics and genomics. 2005. Klein Kathrin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overview of the pharmacogenetics of HIV therapy. The pharmacogenomics journal. 2006. Rodríguez-Nóvoa S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Idiosyncratic drug hepatotoxicity. Nature reviews. Drug discovery. 2005. Kaplowitz Neil. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS (London, England). 2005. van Leth F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and genomics. 2005. Rotger Margalida, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug metabolism and disposition: the biological fate of chemicals. 1999. Riska P, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0597-0046-60
DrugBank:
DB00238
PDB:
NVP
KEGG Compound:
C07263
KEGG Drug:
D00435
PubChem Compound:
4463
PubChem Substance:
197039
46506789
Drugs Product Database (DPD):
2238748
BindingDB:
1434
ChemSpider:
4308
HET:
NVP
Therapeutic Targets Database:
DAP000184
FDA Drug Label at DailyMed:
5ec05500-6333-4bd0-ac83-464fad0d5162

Clinical Trials

These are trials that mention nevirapine and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.